Date: Thu, 18 Dec 1997 20:09:16 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 10824
Last-modified: Fri, 07 Nov 1997 21:35:21 GMT
Non-Invasive Monitoring Systems, Inc.
Non-Invasive Monitoring Systems, Inc.
(Nims)
Nims is Positioned
to Take Advantage of Current Health Care Dynamics
Regulatory
Issues.....
From
1995 onwards, FDA mandates labeling of Apnea Monitors
-
Respitrace Plus:
FDA permission to market as "Obstructive/Mixed/Central Apnea - Heart Rate
Monitor"
-
Impedance (current
market maker): labeled as "Central Apnea-Heart Rate Monitor" New
Ami monitor. (Nellcor-Puritan Bennett) is labeled prominately
on front panel "Infant Central Apnea/Heart Rate Monitor"!
-
Mandatory labeling
with explanation should have major effect on risk liability to users of
"inferior claims" impedance apnea monitor.
-
Respitrace technology
has potential to replace impedance pneumography, the current standard for
apnea detection in NICU and Home Infant Apnea Monitoring locations because
it can detect obstructive/mixed apneas as well as central apneas whereas
impedance pneumography can only detect central apneas. It should be noted
that several studies in the medical literature indicate that obstructive/mixed
apneas lasting greater than 15 seconds comprise over 60% of all apneas
in NICU.
Reimbursement.....
HCFA
changed reimbursement policy for Medicare patients in January '94
-
Favorable reimbursement
for sleep studies with Nims Respitrace technology (respiration, O2 saturation
& heart rate) - pays cost of study.
-
Unfavorable reimbursement
for sleep studies using EEG based multichannel polygraph recordings - financial
loss incurred.
-
Respitrace is
optimal technology for monitoring breathing during sleep.
Emerging
Health Care Trends..... House call by telephone now under evaluation by
HMO's: NY Times Feb. 24, 1997.....
-
On demand evaluation,
better product than fixed appointment house calls.
-
Telemedicine can
minimize abuse and fraud in system.
-
Single nurse visit
can cost up to $104.
-
Cost effective.
-
Widespread usage
reduces cost of manufacturing: savings can be passed onto consumer.
-
Monitoring can
be carried out remotely in regional centers with large population areas.
Nims
current capabilities include non-invasive monitoring of decision making
physiologic parameters
-
Nims' RespiEvents
software measures more cardiopulmonary parameters than any other package
commercially available.
-
RespiEvents software
has enormous expansion capability (New parameters being validated, New
algorithms ongoing studies, Reliable diagnostic software).
10 Top Medical Technologies
for Next Century, Med. Data International Emerging Technology Conference
March 1997
-
Increased Self
Care & Health Literacy
-
Personalized Consumer
Products
-
Human Interfaces
-
"Virtual" Health
Care Delivery Convergence of Technology in
the Home
|
Nims
products in development
for home monitoring and advice comply with these guidelines for emerging
technologies. |
Product
Sales Inquiries:
SensorMedics Corp.
SensorMedics BV
22705 Savi Ranch Parkway
Rembrandtlaan 1b
Yorba Linda, CA 92887 USA
3723 BG Bilthoven
Tel 800 231 2466
The Netherlands
Tel 714 283 8477
Tel 31 30 228 9711
Fax 714 283 8439
Fax 31 30 228 6244
All contents Copyright 1997 Nims, Inc. All rights
reserved.
Respitrace, Respitrace Plus, Respiband are registered
trademarks of Nims, Inc.